HOW WOULD I MANAGE A 68-YEAR-OLD MAN WITH LONGSTANDING TYPE 2 DIABETES WHO HAS SECONDARY FAILURE TO ORAL HYPOGLYCAEMIC AGENTS?

1UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310:83-8.

2UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-65.

3 Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15:737-54.

4UK Prospective Diabetes Study Group. Sulphonylurea failure in non-insulin-dependent diabetic patients over six years (UKPDS 26). Diabetic Med 1998; 15:297-303.

5 Lebovitz HE. Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Revs 1998; 6:132-45.

6UK Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.

7University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes VII: mortality and selected nonfatal events with insulin treatment. JAMA 1978; 240:37-42.

8 Fuhlendorff J P Rorsman Kofod H Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47:345-51.

9 Graul A Castaner J. Repaglinide. Drugs of the Future 1996; 21:694-9.

10 Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Med 1999; 16:1-14.

11 Yki-Jarvinen H L Ryysy Nikkila K Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomised, controlled trial. Ann Intern Med 1999; 130:389-96.

12 Hermann LS. Combination therapy with insulin and metformin. Endocrine Pract 1998; 4:404-12.

13UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12.

14UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-13.

15 Ramsay LE B Williams Johnston GD Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13:569-92.

16Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and macrovascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-9.

17The Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20:614-20.

18 Goldberg RB MJ Mellies Sacks FM for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation 1998; 98:2513-9.

19British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80(Suppl 2):S1-S29.ACKNOWLEDGEMENT